Disease · HP_0000112

Nephropathy

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Nephropathy. Diseases, record HP_0000112. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0000112

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Nephropathy
Open Targets ID: HP_0000112
Highest stage of its drugs: Phase 3, for 2 of its 14 drugs, from ClinicalTrials.gov

Source Open Targets

Drugs14

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PIOGLITAZONE	CHEMBL595	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PYRIDOXAMINE DIHYDROCHLORIDE	CHEMBL4298078		Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ALISKIREN	CHEMBL1639	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
TELMISARTAN	CHEMBL1017	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ATRASENTAN	CHEMBL9194	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
LOSARTAN	CHEMBL191	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
MITAPIVAT	CHEMBL4299940	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PROBUCOL	CHEMBL608	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
SPIRONOLACTONE	CHEMBL1393	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
NCX-4016	CHEMBL374385	Small molecule	Phase 2	TTD	1	0	0	Drugs and targets

1 to 10 of 14

See all 14 drugs

Targets61

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
AGTR1	Type-1 angiotensin II receptor	2	Type-1 angiotensin II receptor antagonist	Phase 2	https://conductscience.org/library/genes/185	Drugs and targets
ABCA1	Phospholipid-transporting ATPase ABCA1	1	ATP-binding cassette sub-family A member 1 inhibitor	Phase 2	https://conductscience.org/library/genes/19	Drugs and targets
ACE	Angiotensin-converting enzyme	1	Angiotensin-converting enzyme inhibitor	Unknown	https://conductscience.org/library/genes/1636	Drugs and targets
COXFA4	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Unknown	https://conductscience.org/library/genes/4697	Drugs and targets
COXFA4L2	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Unknown	https://conductscience.org/library/genes/56901	Drugs and targets
EDNRA	Endothelin-1 receptor	1	Endothelin receptor ET-A antagonist	Phase 2	https://conductscience.org/library/genes/1909	Drugs and targets
GPD2	Glycerol-3-phosphate dehydrogenase, mitochondrial	1	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor	Unknown	https://conductscience.org/library/genes/2820	Drugs and targets
INSR	Insulin receptor	1	Insulin receptor agonist	Unknown	https://conductscience.org/library/genes/3643	Drugs and targets
MC2R	Adrenocorticotropic hormone receptor	1	Melanocortin receptor 2 agonist	Unknown	https://conductscience.org/library/genes/4158	Drugs and targets
MT-ND1	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Unknown	https://conductscience.org/library/genes/4535	Drugs and targets

1 to 10 of 61

See all 61 targets

Trials13

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02138006	Long-term Effects of Intensive Insulin Treatment in Type 1 Diabetes	Not applicable	102	2015-12-21	Coronary Heart Disease, Stroke, Renal Failure	INSULIN HUMAN	Its record names the disease	ClinicalTrials.gov
NCT00097955	Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria	Phase 2	496		Diabetic Nephropathy	ALISKIREN	Its record names the disease	ClinicalTrials.gov
NCT02156843	Pyridorin in Diabetic Nephropathy	Phase 3	328		Diabetic Nephropathy, Diabetic Kidney Disease	PYRIDOXAMINE DIHYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT06570980	Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.		200		Type 2 Diabetes Mellitus (T2DM), Cost-effectiveness, Sulfonylureas, DPP4 Inhibitors, Metformin	METFORMIN	Its record names the disease	ClinicalTrials.gov
NCT01356849	Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor	Phase 2	149		Chronic Kidney Disease, Diabetic Nephropathy	ATRASENTAN	Its record names the disease	ClinicalTrials.gov
NCT01667614	Effects of Spironolactone Combination Therapy on Proteinuria, Kidney Function, and Blood Pressure	Phase 2	136		Type 2 Diabetes Mellitus, Diabetic Nephropathy, Essential Hypertension	LOSARTAN, SPIRONOLACTONE	Its record names the disease	ClinicalTrials.gov
NCT01726816	Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy	Phase 2	126		Diabetic Nephropathy	PROBUCOL	Its record names the disease	ClinicalTrials.gov
NCT05946564	A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial	Phase 3	126		ANCA Associated Vasculitis, Rapidly Progressive Glomerulonephritis, Crescentic Glomerulonephritis	PIOGLITAZONE	Open Targets' reading of its record	ClinicalTrials.gov
NCT04736329	Telmisartan Versus Enalapril in Heart Failure With Reduced Ejection Fraction Patients With Moderately Impaired Kidney Functions	Not applicable	107		Heart Failure With Reduced Ejection Fraction, Renal Insufficiency	ENALAPRIL, TELMISARTAN	Its record names the disease	ClinicalTrials.gov
NCT02187484	BIBR 277 Capsules in Hypertensive Patients With Nephropathy	Phase 2	23		Hypertension	TELMISARTAN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 13

See all 13 trials

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Intensive Insulin Treatment vs Standard Insulin Treatment: Cardiovascular Mortality	7 of 48	11 of 54	102	NCT02138006	Trial comparisons
Intensive Insulin Treatment vs Standard Insulin Treatment: Morbidity of Cardiovascular Complications	6 of 48	11 of 54	102	NCT02138006	Trial comparisons
Intensive Insulin Treatment vs Standard Insulin Treatment: serious adverse events	0 of 48	0 of 54	102	NCT02138006	Trial comparisons

Papers from its trials8

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40569673	DERIVED	1	PubMed
37716952	DERIVED	1	PubMed
37552407	DERIVED	1	PubMed
33107592	DERIVED	1	PubMed
28756065	DERIVED	1	PubMed
27493100	DERIVED	1	PubMed
20693353	DERIVED	1	PubMed
18525041	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0000112

GET https://conductscience.org/api/diseases/v1/HP_0000112/targets?page=2

API reference For AI assistants